Want to see HK:6929 full AI Analyst Report?
6929 Stock Chart & Stats
HK$4.44
HK$0.00(0.00%)
At close: 4:00 PM EST
HK$4.44
HK$0.00(0.00%)
Day’s Range― - ―
52-Week RangeHK$3.45 - HK$5.30
Previous CloseN/A
Volume48.00K
Average Volume (3M)176.23K
Market Cap
HK$3.05B
Enterprise ValueHK$1.33K
Total Cash (Recent Filing)HK$218.68M
Total Debt (Recent Filing)HK$3.91M
Price to Earnings (P/E)9.3
Beta0.58
Next Earnings
Aug 13, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield7.3%
Share Statistics
EPS (TTM)0.05
Shares Outstanding827,968,300
10 Day Avg. Volume244,250
30 Day Avg. Volume176,233
Financial Highlights & Ratios
PEG Ratio1.57
Price to Book (P/B)0.93
Price to Sales (P/S)2.13
P/FCF Ratio333.81
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.05
Revenue Forecast (FY)HK$198.86M
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetVery low leverage and a large equity base provide durable financial flexibility. This conservative capital structure reduces refinancing risk, supports investment in R&D or market expansion, and allows the company to withstand cyclical stress without sacrificing strategic initiatives.
Steady Revenue GrowthConsistent mid-to-high single-digit top-line growth indicates stable demand and secular adoption of the company's interventional devices across markets. Predictable revenue expands scale, supports incremental margin recovery, and underpins longer-term planning for product investment and geographic expansion.
High Gross Margins & Stable ROESustained high gross margins and mid-teens-to-low-double-digit ROE reflect differentiated products and efficient capital use. This structural profitability cushions operating variability, funds reinvestment, and supports long-term returns even if operating expenses rise modestly.
Bears Say
Very Weak Free Cash FlowMaterial decline in free cash flow reduces self-funding capacity for capex, dividends, or acquisitions. Persistent low FCF increases reliance on external financing, limits strategic optionality, and makes funding growth or weathering downturns more costly over the medium term.
Poor Cash ConversionOperating cash flow consistently covering less than net income signals weak cash conversion, likely from higher working capital or noncash accruals. Over time this can erode liquidity, constrain reinvestment, and reduce the reliability of earnings as a source of cash for stakeholders.
Margin Compression Vs 2023 PeakMargins shrinking while revenue rises suggests rising costs, pricing pressure, or mix shifts. Sustained margin compression would reduce free cash flow and returns, limiting ability to fund growth and weakening the company's competitive resilience over the medium term.
OrbusNeich Medical Group Holdings Limited News
6929 FAQ
What was OrbusNeich Medical Group Holdings Limited’s price range in the past 12 months?
OrbusNeich Medical Group Holdings Limited lowest stock price was HK$3.45 and its highest was HK$5.30 in the past 12 months.
What is OrbusNeich Medical Group Holdings Limited’s market cap?
OrbusNeich Medical Group Holdings Limited’s market cap is HK$3.05B.
When is OrbusNeich Medical Group Holdings Limited’s upcoming earnings report date?
OrbusNeich Medical Group Holdings Limited’s upcoming earnings report date is Aug 13, 2026 which is in 4 days.
How were OrbusNeich Medical Group Holdings Limited’s earnings last quarter?
OrbusNeich Medical Group Holdings Limited released its earnings results on Mar 12, 2026. The company reported HK$0.209 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is OrbusNeich Medical Group Holdings Limited overvalued?
According to Wall Street analysts OrbusNeich Medical Group Holdings Limited’s price is currently Overvalued.
Does OrbusNeich Medical Group Holdings Limited pay dividends?
OrbusNeich Medical Group Holdings Limited pays a Notavailable dividend of HK$0.12 which represents an annual dividend yield of 7.3%. See more information on OrbusNeich Medical Group Holdings Limited dividends here
What is OrbusNeich Medical Group Holdings Limited’s EPS estimate?
OrbusNeich Medical Group Holdings Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does OrbusNeich Medical Group Holdings Limited have?
OrbusNeich Medical Group Holdings Limited has 827,968,300 shares outstanding.
What happened to OrbusNeich Medical Group Holdings Limited’s price movement after its last earnings report?
OrbusNeich Medical Group Holdings Limited reported an EPS of HK$0.209 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.104%.
Which hedge fund is a major shareholder of OrbusNeich Medical Group Holdings Limited?
Currently, no hedge funds are holding shares in HK:6929
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
OrbusNeich Medical Group Holdings Limited Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-4.87%
12-Months-Change
Fundamentals
Return on Equity
7.30%
Trailing 12-Months
Asset Growth
5.29%
Trailing 12-Months
Company Description
OrbusNeich Medical Group Holdings Limited
OrbusNeich Medical Group Holdings Limited functions as an investment holding entity, specializing in the development, distribution, sales, and marketing of medical instruments tailored for treating coronary and peripheral vascular ailments. The company boasts a significant international presence, serving markets across Japan, Europe, the Middle East, Africa, the Asia Pacific region, the People's Republic of China, and the United States. Its product offerings encompass a range of essential devices, including semi-compliant and scoring balloons used for initial vessel preparation, coronary stents for implantation, non-compliant balloons designed for post-dilatation, and a variety of specialized catheters. This extensive portfolio of products addresses critical steps within percutaneous coronary intervention (PCI) and percutaneous transluminal angioplasty (PTA) procedures. Founded in 2001, the company is headquartered in Shatin, Hong Kong, and operates as a subsidiary of Harmony Tree Limited.
Technical Analysis
Shandong Weigao Group Medical Polymer Co
―
PW Medtech Group Ltd.
―
Modern Dental Group Limited
―
Shanghai Kindly Medical Instruments Co., Ltd. Class H
―
Angelalign Technology Inc.
―